1.Mitochondrial Ribosomal Protein L14 Promotes Cell Growth and Invasion by Modulating Reactive Oxygen Species in Thyroid Cancer
Hae Jong KIM ; Quoc Khanh NGUYEN ; Seung-Nam JUNG ; Mi Ae LIM ; Chan OH ; Yudan PIAO ; YanLi JIN ; Ju-Hui KIM ; Young Il KIM ; Yea Eun KANG ; Jae Won CHANG ; Ho-Ryun WON ; Bon Seok KOO
Clinical and Experimental Otorhinolaryngology 2023;16(2):184-197
Objectives:
. The mitochondrial ribosomal protein L14 (MRPL14) is encoded by a nuclear gene and participates in mitochondrial protein translation. In this study, we aimed to investigate the role of MRPL14 in thyroid cancer.
Methods:
. We investigated the association between MRPL14 expression and clinicopathological features using The Cancer Genome Atlas (TCGA) and Chungnam National University Hospital (CNUH) databases. Functional studies of MRPL14, including proliferation, migration, invasion, mitochondrial oxidative phosphorylation and reactive oxygen species (ROS) production, were performed in papillary thyroid cancer (PTC) cell lines (B-CPAP and KTC-1).
Results:
. Based on the TCGA dataset, PTC tissues lost mitochondrial integrity and showed dysregulated expression of overall mitoribosomal proteins (MRPs) compared with normal thyroid tissues. Of 78 MRPs, MRPL14 was highly expressed in thyroid cancer tissues. MRPL14 overexpression was significantly associated with advanced tumor stage, extrathyroidal extension, and lymph node metastasis. MRPL14 increased cell proliferation of thyroid cancer and promoted cell migration via epithelial-mesenchymal transition-related proteins. Moreover, MRPL14 knockdown reduced the expression of oxidative phosphorylation complex IV (MTCO1) and increased the accumulation of ROS. Cotreatment with a ROS scavenger restored cell proliferation and migration, which had been reduced by MRPL14 knockdown, implying that ROS functions as a key regulator of the oncogenic effects of MRPL14 in thyroid cancer cells.
Conclusion
. Our findings indicate that MRPL14 may promote cell growth, migration, and invasion by modulating ROS in thyroid cancer cells.
2.2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism
Hyun Kyung CHUNG ; Eu Jeong KU ; Won Sang YOO ; Yea Eun KANG ; Kyeong Jin KIM ; Bo Hyun KIM ; Tae-Yong KIM ; Young Joo PARK ; Chang Ho AHN ; Jee Hee YOON ; Eun Kyung LEE ; Jong Min LEE ; Eui Dal JUNG ; Jae Hoon CHUNG ; Yun Jae CHUNG ; Won Bae KIM ; Ka Hee YI ; Ho-Cheol KANG ; Do Joon PARK
International Journal of Thyroidology 2023;16(1):32-50
Subclinical hypothyroidism (SCH), characterized by elevated serum thyroid-stimulating hormone (TSH) levels and normal free thyroxine levels, usually presents without symptoms, and is often discovered incidentally during routine blood test. The Task Force of the Korean Thyroid Association Committee of Clinical Practice Guidelines has established a guideline to evaluate and manage SCH; the guideline emphasizes the implementation of diagnostic criteria based on the TSH reference range for Koreans and focuses on the proven health benefits of levothyroxine (LT4) treatment. Based on the Korea National Health and Nutrition Examination Survey (2013-2015), serum TSH level of 6.8 mIU/L is considered the reference value for SCH. SCH can be categorized as mild (TSH 6.8-10.0 mIU/L) or severe (TSH >10.0 mIU/L), and patients are classified as adults (age <70 years) or elderly patients (age ≥70years) depending on the health effects of LT4 treatment. An initial increase in serum TSH levels should be reassessed with a subsequent measurement, along with the thyroid peroxidase antibody test, preferably 2-3 months after the initial evaluation. Usually, LT4 treatment is not recommended for mild SCH in adults; however, treatment is necessary for severe SCH in patients with underlying coronary artery disease or heart failure and can be considered for coexisting dyslipidemia. LT4 treatment is not recommended for mild or even severe SCH in elderly patients, in general. Patients with SCH who receive LT4 treatment, the LT4 dosage should be personalized, and serum TSH levels should be monitored to ensure optimal LT4 dosage (dosage that is neither excessive nor insufficient). Patients with SCH who do not receive LT4 treatment require periodic follow-up at appropriate testing intervals determined by disease severity. The guideline also provides several educational points applicable in clinical settings.
3.2023 Korean Thyroid Association Management Guidelines for Patients with Subclinical Hypothyroidism
Hyun Kyung CHUNG ; Eu Jeong KU ; Won Sang YOO ; Yea Eun KANG ; Kyeong Jin KIM ; Bo Hyun KIM ; Tae-Yong KIM ; Young Joo PARK ; Chang Ho AHN ; Jee Hee YOON ; Eun Kyung LEE ; Jong Min LEE ; Eui Dal JUNG ; Jae Hoon CHUNG ; Yun Jae CHUNG ; Won Bae KIM ; Ka Hee YI ; Ho-Cheol KANG ; Do Joon PARK
International Journal of Thyroidology 2023;16(2):214-215
4.Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
Seung-Jin PARK ; Yea Eun KANG ; Jeong-Hwan KIM ; Jong-Lyul PARK ; Seon-Kyu KIM ; Seung-Woo BAEK ; In Sun CHU ; Shinae YI ; Seong Eun LEE ; Young Joo PARK ; Eun-Jae CHUNG ; Jin Man KIM ; Hye Mi KO ; Je-Ryong KIM ; Seung-Nam JUNG ; Ho-Ryun WON ; Jae Won CHANG ; Bon Seok KOO ; Seon-Young KIM
Clinical and Experimental Otorhinolaryngology 2022;15(2):183-193
Objectives:
. Thyroid cancer is the most common endocrine tumor, with rapidly increasing incidence worldwide. However, its transcriptomic characteristics associated with immunological signatures, driver fusions, and recurrence markers remain unclear. We aimed to investigate the transcriptomic characteristics of advanced papillary thyroid cancer.
Methods:
. This study included 282 papillary thyroid cancer tumor samples and 155 normal samples from Chungnam National University Hospital and Seoul National University Hospital. Transcriptomic quantification was determined by high-throughput RNA sequencing. We investigated the associations of clinical parameters and molecular signatures using RNA sequencing. We validated predictive biomarkers using the Cancer Genome Atlas database.
Results:
. Through a comparison of differentially expressed genes, gene sets, and pathways in papillary thyroid cancer compared to normal tumor-adjacent tissue, we found increased immune signaling associated with cytokines or T cells and decreased thyroid hormone synthetic pathways. In addition, patients with recurrence presented increased CD8+ T-cell and Th1-cell signatures. Interestingly, we found differentially overexpressed genes related to immune-escape signaling such as CTLA4, IDO1, LAG3, and PDCD1 in advanced papillary thyroid cancer with a low thyroid differentiation score. Fusion analysis showed that the PI3K and mitogen-activated protein kinase (MAPK) signaling pathways were regulated differently according to the RET fusion partner genes (CCDC6 or NCOA4). Finally, we identified HOXD9 as a novel molecular biomarker that predicts the recurrence of thyroid cancer in addition to known risk factors (tumor size, lymph node metastasis, and extrathyroidal extension).
Conclusion
. We identified a high association with immune-escape signaling in the immune-hot group with aggressive clinical characteristics among Korean thyroid cancer patients. Moreover, RET fusion differentially regulated PI3K and MAPK signaling depending on the partner gene of RET, and HOXD9 was found to be a recurrence marker for advanced papillary thyroid cancer.
5.Malignant intercostal psammomatous melanotic schwannoma in a patient with Carney complex.
Yea Eun KANG ; Jin Ok JEONG ; Kyung Hee KIM ; Chang Seok KI ; Hyun Jin KIM
The Korean Journal of Internal Medicine 2018;33(6):1256-1257
No abstract available.
Carney Complex*
;
Humans
;
Neurilemmoma*
6.Galangin Activates the ERK/AKT-Driven Nrf2 Signaling Pathway to Increase the Level of Reduced Glutathione in Human Keratinocytes.
Susara Ruwan Kumara Madduma HEWAGE ; Mei Jing PIAO ; Kyoung Ah KANG ; Yea Seong RYU ; Pattage Madushan Dilhara Jayatissa FERNANDO ; Min Chang OH ; Jeong Eon PARK ; Kristina SHILNIKOVA ; Yu Jin MOON ; Dae O SHIN ; Jin Won HYUN
Biomolecules & Therapeutics 2017;25(4):427-433
Previously, we demonstrated that galangin (3,5,7-trihydroxyflavone) protects human keratinocytes against ultraviolet B (UVB)-induced oxidative damage. In this study, we investigated the effect of galangin on induction of antioxidant enzymes involved in synthesis of reduced glutathione (GSH), and investigated the associated upstream signaling cascades. By activating nuclear factor-erythroid 2-related factor (Nrf2), galangin treatment significantly increased expression of glutamate-cysteine ligase catalytic subunit (GCLC) and glutathione synthetase (GSS). This activation of Nrf2 depended on extracellular signal-regulated kinases (ERKs) and protein kinase B (AKT) signaling. Inhibition of GSH in galangin-treated cells attenuated the protective effect of galangin against the deleterious effects of UVB. Our results reveal that galangin protects human keratinocytes by activating ERK/AKT-Nrf2, leading to elevated expression of GSH-synthesizing enzymes.
Catalytic Domain
;
Extracellular Signal-Regulated MAP Kinases
;
Glutamate-Cysteine Ligase
;
Glutathione Synthase
;
Glutathione*
;
Humans*
;
Keratinocytes*
;
Proto-Oncogene Proteins c-akt
7.Selective Radiation Therapy for Ductal Carcinoma In Situ Following Breast-Conserving Surgery According to Age and Margin Width: Korean Radiation Oncology Group 11-04 and 16-02 Studies.
Kyubo KIM ; Jin Hee KIM ; Yong Bae KIM ; Chang Ok SUH ; Kyung Hwan SHIN ; Jin Ho KIM ; Tae Hyun KIM ; So Youn JUNG ; Doo Ho CHOI ; Won PARK ; Seung Do AHN ; Su Ssan KIM ; Ji Woon YEA ; Min Kyu KANG ; Dong Won KIM ; Yi Jun KIM
Journal of Breast Cancer 2017;20(4):327-332
PURPOSE: The optimal indications for omitting adjuvant radiation therapy (RT) after breast-conserving surgery are still controversial in ductal carcinoma in situ (DCIS) of the breast. The purpose of this study was to validate the role of postoperative RT in DCIS patients aged ≤50 years and with tumor margin widths of <1 cm, both of which have been proven to be high-risk features for recurrence in cohorts not receiving RT. METHODS: Using two multicenter retrospective studies on DCIS, a pooled analysis was performed among patients aged ≤50 years and with margin widths < 1 cm. All patients underwent breast-conserving surgery. Two hundred thirty-two patients received postoperative RT, while 54 did not. The median follow-up period was 77 months (range, 2–190 months) and 70 months (range, 5–166 months) in the patients who received RT and those who did not, respectively. RESULTS: The patients who received RT had larger tumors (p < 0.001), higher nuclear grade (p < 0.001), closer margin width (p < 0.001), and negative estrogen receptor expression (p=0.010) compared with those who did not receive RT. During the follow-up period, there were 17 ipsilateral breast tumor recurrences (IBTRs) as follows: invasive carcinoma in 10 patients and DCIS in seven. In the univariate analysis, the treatment with RT and human epidermal growth factor receptor 2 (HER2) status were significant risk factors for IBTR. The 7-year IBTR rates with and without postoperative RT were 3.6% and 13.1%, respectively (p=0.008). HER2-positive tumors had a higher IBTR rate than the HER2-negative tumors (7-year rate, 13.6% vs. 3.9%; p=0.003). CONCLUSION: Postoperative RT following breast-conserving surgery significantly reduced the 7-year IBTR rate in the DCIS patients aged ≤50 years and with margin widths < 1 cm. HER2 positivity was associated with increased IBTR in these patients.
Age Factors
;
Breast
;
Breast Neoplasms
;
Carcinoma, Ductal*
;
Carcinoma, Intraductal, Noninfiltrating*
;
Cohort Studies
;
Estrogens
;
Follow-Up Studies
;
Humans
;
Mastectomy, Segmental*
;
Radiation Oncology*
;
Radiotherapy
;
Receptor, Epidermal Growth Factor
;
Recurrence
;
Retrospective Studies
;
Risk Factors
8.Reduced Autophagy in 5-Fluorouracil Resistant Colon Cancer Cells.
Cheng Wen YAO ; Kyoung Ah KANG ; Mei Jing PIAO ; Yea Seong RYU ; Pattage Madushan Dilhara Jayatissa FERNANDO ; Min Chang OH ; Jeong Eon PARK ; Kristina SHILNIKOVA ; Soo Young NA ; Seung Uk JEONG ; Sun Jin BOO ; Jin Won HYUN
Biomolecules & Therapeutics 2017;25(3):315-320
We investigated the role of autophagy in SNUC5/5-FUR, 5-fluorouracil (5-FU) resistant SNUC5 colon cancer cells. SNUC5/5-FUR cells exhibited low level of autophagy, as determined by light microscopy, confocal microscopy, and flow cytometry following acridine orange staining, and the decreased level of GFP-LC3 puncta. In addition, expression of critical autophagic proteins such as Atg5, Beclin-1 and LC3-II and autophagic flux was diminished in SNUC5/5-FUR cells. Whereas production of reactive oxygen species (ROS) was significantly elevated in SNUC5/5-FUR cells, treatment with the ROS inhibitor N-acetyl cysteine further reduced the level of autophagy. Taken together, these results indicate that decreased autophagy is linked to 5-FU resistance in SNUC5 colon cancer cells.
Acridine Orange
;
Autophagy*
;
Colon*
;
Colonic Neoplasms*
;
Cysteine
;
Flow Cytometry
;
Fluorouracil*
;
Microscopy
;
Microscopy, Confocal
;
Reactive Oxygen Species
9.Hesperidin Attenuates Ultraviolet B-Induced Apoptosis by Mitigating Oxidative Stress in Human Keratinocytes.
Susara Ruwan Kumara Madduma HEWAGE ; Mei Jing PIAO ; Kyoung Ah KANG ; Yea Seong RYU ; Xia HAN ; Min Chang OH ; Uhee JUNG ; In Gyu KIM ; Jin Won HYUN
Biomolecules & Therapeutics 2016;24(3):312-319
Human skin cells undergo pathophysiological processes via generation of reactive oxygen species (ROS) upon excessive exposure to ultraviolet B (UVB) radiation. This study investigated the ability of hesperidin (C28H34O15) to prevent apoptosis due to oxidative stress generated through UVB-induced ROS. Hesperidin significantly scavenged ROS generated by UVB radiation, attenuated the oxidation of cellular macromolecules, established mitochondrial membrane polarization, and prevented the release of cytochrome c into the cytosol. Hesperidin downregulated expression of caspase-9, caspase-3, and Bcl-2-associated X protein, and upregulated expression of B-cell lymphoma 2. Hesperidin absorbed wavelengths of light within the UVB range. In summary, hesperidin shielded human keratinocytes from UVB radiation-induced damage and apoptosis via its antioxidant and UVB absorption properties.
Absorption
;
Apoptosis*
;
bcl-2-Associated X Protein
;
Caspase 3
;
Caspase 9
;
Cytochromes c
;
Cytosol
;
Hesperidin*
;
Humans*
;
Keratinocytes*
;
Lymphoma, B-Cell
;
Mitochondrial Membranes
;
Oxidative Stress*
;
Reactive Oxygen Species
;
Skin
10.Hyperoside Induces Endogenous Antioxidant System to Alleviate Oxidative Stress.
Ji Young PARK ; Xia HAN ; Mei Jing PIAO ; Min Chang OH ; Pattage Madushan Dilhara Jayatissa FERNANDO ; Kyoung Ah KANG ; Yea Seong RYU ; Uhee JUNG ; In Gyu KIM ; Jin Won HYUN
Journal of Cancer Prevention 2016;21(1):41-47
BACKGROUND: Hyperoside, a flavonoid which is mainly found in Hypericum perforatum L., has many biological effects. One of the most important effects is to prevent the oxidative stress induced by reactive oxygen species. However, the molecular mechanisms underlying its effect are not fully understood. Oxidative stress is implicated in the occurrence of various physical diseases. A wide array of enzymatic antioxidant defense systems include NADH: quinone oxidoreductase 1, superoxide dismutase, and heme oxygenase-1 (HO-1). In the present study, the protective effects of hyperoside against hydrogen peroxide-induced oxidative stress in human lens epithelial cells, HLE-B3, were investigated in terms of HO-1 induction. METHODS: The protein and mRNA expressions of HO-1 were examined by Western blotting and reverse transcriptase-PCR assays, respectively. To evaluate the ability of hyperoside to activate nuclear factor erythroid 2-related factor 2 (Nrf2), Western blotting and electrophoretic mobility shift assay were performed with nuclear extracts prepared from HLE-B3 cells treated with hyperoside. The activation of extracellular signal-regulated kinase (ERK), the upstream kinase of Nrf2 signaling, was monitored by Western blot analysis. The protective effect of hyperoside in HLE-B3 cells against hydrogen peroxide was performed by MTT assay. RESULTS: Hyperoside increased both the mRNA and protein expression of HO-1 in a time- and dose-dependent manner. In addition, hyperoside elevated the level of of Nrf2 and its antioxidant response element-binding activity, which was modulated by upstream of ERK. Moreover, it activated ERK and restored cell viability which was decreased by hydrogen peroxide. CONCLUSIONS: Hyperoside is an effective compound to protect cells against oxidative stress via HO-1 induction.
Antioxidants
;
Blotting, Western
;
Cell Survival
;
Electrophoretic Mobility Shift Assay
;
Epithelial Cells
;
Heme Oxygenase-1
;
Humans
;
Hydrogen
;
Hydrogen Peroxide
;
Hypericum
;
NAD
;
Oxidative Stress*
;
Phosphotransferases
;
Reactive Oxygen Species
;
RNA, Messenger
;
Superoxide Dismutase

Result Analysis
Print
Save
E-mail